Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.88
- Piotroski Score 2.00
- Grade Hold
- Symbol (ZYNE)
- Company Zynerba Pharmaceuticals, Inc.
- Price $1.30
- Changes Percentage (2.36%)
- Change $0.03
- Day Low $1.26
- Day High $1.34
- Year High $1.40
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2023
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.79
- Trailing P/E Ratio -1.6455696202532
- Forward P/E Ratio -1.6455696202532
- P/E Growth -1.6455696202532
- Net Income $-34,820,072
Income Statement
Quarterly
Annual
Latest News of ZYNE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Zynex's (NASDAQ:ZYXI) Returns On Capital Not Reflecting Well On The Business
To identify a stock with potential for long-term value growth, look for increasing Return on Capital Employed (ROCE) and rising capital employed....
By Yahoo! Finance | 1 month ago -
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 36%?
An analyst has set a price target for Zynex, Inc. (ZYXI) at US$21.00, 50% above the fair value estimate using a Discounted Cash Flow (DCF) model. The valuation considers projected cash flows and growt...
By Yahoo! Finance | 2 months ago